Press coverage about Adamis Pharmaceuticals (NASDAQ:ADMP) has trended somewhat positive on Sunday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 46.2891023643487 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates (finance.yahoo.com)
- Adamis Pharmaceuticals (ADMP) Announces Earnings Results (americanbankingnews.com)
- Adamis Pharmaceuticals misses on revenue (seekingalpha.com)
- Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update (finance.yahoo.com)
- Adamis: 2Q Earnings Snapshot (finance.yahoo.com)
Adamis Pharmaceuticals stock remained flat at $$3.25 during mid-day trading on Friday. 537,007 shares of the company’s stock were exchanged, compared to its average volume of 656,420. The firm has a market capitalization of $108.52 million, a P/E ratio of -3.61 and a beta of 0.45. The company has a current ratio of 1.88, a quick ratio of 1.57 and a debt-to-equity ratio of 0.07. Adamis Pharmaceuticals has a 1 year low of $2.35 and a 1 year high of $5.85.
Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings data on Friday, August 10th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.10). The business had revenue of $3.92 million during the quarter, compared to analyst estimates of $4.14 million. Adamis Pharmaceuticals had a negative return on equity of 71.68% and a negative net margin of 207.24%. research analysts predict that Adamis Pharmaceuticals will post -0.69 EPS for the current year.
A number of analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 27th. B. Riley lifted their price target on shares of Adamis Pharmaceuticals to $7.50 and gave the stock a “buy” rating in a research note on Tuesday, July 3rd. Maxim Group lifted their price target on shares of Adamis Pharmaceuticals to $13.00 and gave the stock a “buy” rating in a research note on Monday, July 2nd. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Adamis Pharmaceuticals in a research note on Monday, July 2nd. Finally, ValuEngine upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $8.40.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.